Nkarta, Inc. (NKTX)

$13.55

+1.08 (+8.66%)
Rating:
Recommendation:
-
Symbol NKTX
Price $13.55
Beta 0.000
Volume Avg. 2.96M
Market Cap 662.716M
Shares () -
52 Week Range 7.55-40.64
1y Target Est -
DCF Unlevered NKTX DCF ->
DCF Levered NKTX LDCF ->
ROE -35.72% Strong Sell
ROA -30.26% Strong Sell
Operating Margin -
Debt / Equity 33.93% Neutral
P/E -
P/B 1.95 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest NKTX news


Mr. Paul J. Hastings
Healthcare
Biotechnology
NASDAQ Global Select

Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.